Induction chemotherapy and concurrent chemoradiotherapy with cisplatin for T4 nasoethmoidal squamous cell carcinoma: The value of paclitaxel, carboplatin and cetuximab (PCE)

•The optimal therapy for locally advanced sinonasal SCC is still undetermined.•Induction chemotherapy in non-surgically-treated T4 sinonasal SCC was assessed.•IC-PCE yielded an ORR of 80% with a favorable safety profile (Gr3 AEs: 20%).•Adding IC-PCE before chemoradiotherapy provided excellent progno...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Oral oncology Ročník 163; s. 107235
Hlavní autori: Tanaka, Nobukazu, Enokida, Tomohiro, Okano, Susumu, Fujisawa, Takao, Tanaka, Hideki, Onaga, Ryutaro, Hoshi, Yuta, Kishida, Takuma, Wada, Akihisa, Sato, Masanobu, Takeshita, Naohiro, Fujisawa, Takeshi, Motegi, Atsushi, Zenda, Sadamoto, Akimoto, Tetsuo, Tahara, Makoto
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Elsevier Ltd 01.04.2025
Predmet:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carboplatin - pharmacology
Carboplatin - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - therapy
Cetuximab - administration & dosage
Cetuximab - pharmacology
Cetuximab - therapeutic use
Chemoradiotherapy
Chemoradiotherapy - methods
Cisplatin - administration & dosage
Cisplatin - pharmacology
Cisplatin - therapeutic use
Female
Hematology, Oncology, and Palliative Medicine
Humans
Induction chemotherapy
Induction Chemotherapy - methods
Intensity modulated radiotherapy
Male
Middle Aged
Nose Neoplasms - pathology
Nose Neoplasms - therapy
Otolaryngology
Paclitaxel - administration & dosage
Paclitaxel - pharmacology
Paclitaxel - therapeutic use
PCE
Proton beam therapy
Retrospective Studies
Sinonasal malignancy
Squamous cell carcinoma
Squamous cell carcinoma
Induction chemotherapy
Intensity modulated radiotherapy
PCE
Sinonasal malignancy
Chemoradiotherapy
Proton beam therapy
ISSN:1368-8375, 1879-0593, 1879-0593
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:•The optimal therapy for locally advanced sinonasal SCC is still undetermined.•Induction chemotherapy in non-surgically-treated T4 sinonasal SCC was assessed.•IC-PCE yielded an ORR of 80% with a favorable safety profile (Gr3 AEs: 20%).•Adding IC-PCE before chemoradiotherapy provided excellent prognosis (3-y RFS: 90%). Locally advanced nasoethmoidal squamous cell carcinoma (SCC) is rare and often unsuitable for surgical resection. Data on the potential clinical benefits of combining induction chemotherapy (IC) and sequential definitive chemoradiotherapy for this condition is limited. We retrospectively investigated T4 nasoethmoidal SCC patients who underwent proton or photon chemoradiotherapy with curative intent at the National Cancer Center Hospital East between April 2014 and May 2022. Patients were categorized into three groups based on IC regimen: no IC (No-IC), paclitaxel plus carboplatin plus cetuximab (IC-PCE), and docetaxel plus cisplatin plus S-1 (IC-TPS). Twenty-five patients were analyzed (No IC, 9; IC-PCE, 10; and IC-TPS, 6). The IC-PCE group had the highest ratio of Stage IVB to IVA patients. IC-PCE and IC-TPS yielded objective responses in eight (80 %) and two (33 %) patients, respectively. All subjects completed radiotherapy, with the median relative to dose intensity of concurrent cisplatin reaching 100 % in all groups. Complete responses were observed in 22 patients. Three patients in the No IC or IC-TPS group showed a partial response after the completion of planned treatment. On a median follow-up of 42 months, the 3-year recurrence-free survival (RFS) rate was 90.0 % in the IC-PCE group and 33.3 % in the remaining groups. Of note, the IC-PCE group had significantly better RFS (log-rank p-value; 0.023) despite no differences in overall survival, time-to-locoregional progression, or time-to-distant metastasis. Sequential IC-PCE followed by concurrent chemoradiotherapy with cisplatin appears promising as an effective therapeutic strategy for T4 nasoethmoidal SCC.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1368-8375
1879-0593
1879-0593
DOI:10.1016/j.oraloncology.2025.107235